title: Rituximab maintenance in indolent lymphoma: indications and controversies.
abstract: Over the past few years it has been shown in previously untreated and relapsed/refractory follicular lymphoma that rituximab maintenance has a clear clinical benefit after induction with rituximab plus chemotherapy, chemotherapy alone, or rituximab monotherapy. However, the optimal dose, schedule, and duration of rituximab maintenance therapy still need to be established. The important issue of maintenance treatment versus retreatment upon relapse is the topic of the ongoing large randomized phase III Rituximab Extended Schedule or Retreatment Trial (RESORT). Current data indicate that rituximab maintenance can be safely administered for up to 2 years, although assessment of long-term safety requires longer follow-up.
authors: Department of Hematology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. M.H.vanOers@AMC.UVA.NL
authors: Marinus H J
authors: MH
authors: van Oers
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
references: J Clin Oncol. 1998 Apr;16(4):1538-46
references: 9580385
references: Br J Cancer. 2001 Jul 6;85(1):29-35
references: 11437398
references: J Clin Oncol. 1995 Jul;13(7):1726-33
references: 7602362
references: Blood. 2005 Feb 15;105(4):1417-23
references: 15494430
references: J Clin Oncol. 2000 May;18(10 ):2010-6
references: 10811664
references: Blood. 2004 Jun 15;103(12):4416-23
references: 14976046
references: J Clin Oncol. 2005 Feb 20;23(6):1096-102
references: 15657402
references: Cancer. 1987 Jul 15;60(2):156-60
references: 3297278
references: Clin Cancer Res. 1999 Mar;5(3):611-5
references: 10100713
references: Ann Oncol. 1998 Sep;9(9):995-1001
references: 9818074
references: Blood. 2006 Dec 15;108(13):4003-8
references: 16946304
references: J Clin Oncol. 1998 Jan;16(1):41-7
references: 9440721
references: J Clin Oncol. 2005 Apr 1;23 (10 ):2215-23
references: 15684317
references: Blood. 2005 Dec 1;106(12):3725-32
references: 16123223
references: J Clin Oncol. 2005 Feb 20;23(6):1088-95
references: 15657401
references: J Clin Oncol. 2002 Oct 15;20(20):4261-7
references: 12377971
references: J Clin Oncol. 1995 Jan;13(1):140-7
references: 7799014
references: Leuk Lymphoma. 1996 Feb;20(5-6):495-9
references: 8833409
references: Blood. 2004 Nov 15;104(10):3064-71
references: 15284112
references: Clin Oncol (R Coll Radiol). 2006 Mar;18(2):155-6
references: 16523821
references: Br J Haematol. 1999 Aug;106(2):571-2
references: 10460626
references: Cancer Treat Rev. 2005 Oct;31(6):456-73
references: 16054760
references: Blood. 2006 Nov 15;108(10):3295-301
references: 16873669
references: Cancer. 1988 Feb 1;61(3):441-7
references: 3338014
references: Ann Oncol. 2000;11 Suppl 1:123-6
references: 10707793
references: J Clin Oncol. 1998 Aug;16(8):2825-33
references: 9704735